GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kringle Pharma 4884.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

496

+4.20%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

¥72.2m

FY2018FY2025

Net income

−¥916.3m

FY2018FY2025

Free cash flow

−¥1.51bn

FY2018FY2025

Shareholders' equity

¥1.31bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue¥72.2m¥80.0m¥69.3m¥391.8m¥289.8m¥467.6m——
Research and development¥681.4m¥643.3m¥716.8m¥533.3m¥398.5m¥489.5m¥265.8m¥156.7m
Operating income−¥909.5m−¥817.9m−¥888.8m−¥426.2m−¥357.9m−¥171.6m−¥371.7m−¥223.6m
Net income−¥916.3m−¥756.5m−¥854.2m−¥331.8m−¥301.2m−¥117.8m−¥302.1m−¥64.6m
Diluted earnings per share-128.00-111.07-148.82-61.67-67.74-32.03-36.03-7.70

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets¥2.08bn¥2.76bn¥2.62bn¥3.21bn¥2.64bn¥2.35bn¥251.9m¥566.9m
Cash and short-term investments¥1.62bn¥2.31bn¥2.14bn¥2.76bn¥2.14bn¥2.10bn¥166.5m¥505.3m
Total liabilities¥770.1m¥648.9m¥597.0m¥419.5m¥129.5m¥161.7m¥35.5m¥48.5m
Shareholders' equity¥1.31bn¥2.11bn¥2.02bn¥2.79bn¥2.51bn¥2.19bn¥216.4m¥518.4m
Shares outstanding7m7m6m5m4m4m8m8m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−¥755.8m−¥661.2m−¥689.1m¥15.8m−¥560.9m−¥146.5m−¥338.8m−¥202.4m
Capital spending−¥755.8m———————
Free cash flow−¥1.51bn−¥661.2m−¥689.1m¥15.8m−¥560.9m−¥146.5m−¥338.8m−¥202.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥287.2m¥17.4m¥18.6m¥18.3m¥18.0m¥17.8m¥18.2m¥18.5m
Operating income−¥118.7m−¥315.4m−¥199.9m−¥170.9m−¥226.6m−¥299.7m−¥212.2m−¥238.2m
Net income−¥115.1m−¥314.7m−¥201.8m−¥176.8m−¥227.0m−¥299.8m−¥212.7m−¥238.0m
Diluted earnings per share-13.73-37.55-28.20-24.69-31.71-41.88-31.23-34.95
Cash from operations———−¥755.0m————
Capital spending———−¥755.0m————
Free cash flow———−¥1.51bn————
Total assets¥2.00bn¥1.99bn¥1.99bn¥2.08bn¥2.11bn¥2.29bn¥2.54bn¥2.76bn
Cash and short-term investments¥1.70bn¥1.59bn¥1.51bn¥1.62bn¥1.63bn¥1.89bn¥2.10bn¥2.31bn
Shareholders' equity¥1.25bn¥947.9m¥1.22bn¥1.31bn¥1.39bn¥1.61bn¥1.90bn¥2.11bn

Financial ratios

Data as of 25 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-1259.4%-2042.6%-2515.0%-193.0%-123.5%-73.5%
Net margin-1268.8%-945.1%-1233.4%-84.7%-103.9%-25.2%
Return on equity-70.0%-35.9%-42.2%-11.9%-12.0%-5.4%
Return on assets-44.1%-27.4%-32.6%-10.3%-11.4%-5.0%
Free cash flow yield-17.3%-15.9%-19.7%0.5%-20.7%-6.5%
Revenue growth-9.8%15.6%-82.3%35.2%-38.0%—
Earnings growth21.1%-11.4%157.4%10.2%155.6%-61.0%
Current ratio18.80x21.50x12.52x19.70x20.71x14.73x
Debt to equity———0.00x0.00x0.00x
Equity ratio63.0%76.5%77.2%86.9%95.1%93.1%
Interest coverage————-54.17x-46.21x
R&D as a share of sales943.5%803.7%1035.1%136.1%137.5%104.7%
Buybacks as a share of market value-5.1%-18.7%-6.7%-21.0%-20.8%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-43.1%-31.2%—
Operating income28.7%39.6%—
Net income40.3%50.7%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-1134.5%-496.0%-260.6%—
Net margin-1098.6%-466.1%-239.1%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-3.0-7.9-5.0-9.3-10.0-41.4
Price to sales38.674.362.37.810.410.4

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.